Lacipil (Lacidipine)

Lacidipine blocks L‑type calcium channels in the smooth muscle of arteries. This inhibition reduces calcium entry into the cells, preventing contraction and causing the blood vessels to relax. The resulting vasodilation decreases peripheral resistance and lowers systemic blood pressure.

The appropriate dose of Lacipil is individualized by the prescribing healthcare professional based on the patient’s blood‑pressure readings, age, renal and hepatic function, and any concomitant medications. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for lacidipine in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and a healthcare provider should be consulted.

To request Lacipil, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lacipil belongs to the dihydropyridine calcium‑channel blocker class, which primarily causes arterial vasodilation. Compared with beta‑blockers or ACE inhibitors, it has a more pronounced effect on peripheral resistance and a lower impact on heart rate, making it useful when vasodilation is the desired primary mechanism.

Lacipil tablets should be stored at room temperature, below 25 °C, in the original packaging. They must be kept away from excess moisture, heat and direct sunlight to maintain stability and potency throughout their shelf life.

Lacipil is taken orally, usually once daily, with or without food as directed by a physician. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed by a healthcare professional.

The most serious adverse events linked to Lacipil include severe hypotension, acute myocardial infarction and angioedema. Patients should be educated to recognize signs such as sudden dizziness, chest pain or swelling of the face and throat and seek immediate medical attention if they occur.

Lacipil is contraindicated in individuals with known hypersensitivity to lacidipine or any other dihydropyridine calcium‑channel blockers. It should also be avoided in patients with severe aortic stenosis or those who have experienced a prior severe hypotensive reaction to similar agents.